{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"66.1","upperLimit":"80.0","value":"73.5"},{"groupId":"OG001","lowerLimit":"57.1","upperLimit":"78.1","value":"68.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"A patient has disease control if the patient has a best tumor response on-study of CR, PR, or SD (Stable disease). DCR was defined as a percentage of patients achieving CR, PR, or SD per mRECIST criteria, as determined by the central radiological reviewer. DCR was calculated in each treatment arm as the number of patients with disease control (a best tumor response on-study of CR, PR, or SD) divided by the number of randomized patients.","dispersionType":"95% Confidence Interval","groups":[{"description":"Test drug: 6.5 mg/kg every 3 weeks; Intravenous (IV) infusion over 1 hour","id":"OG000","title":"Anetumab Ravtansine"},{"description":"Active comparator: 30 mg/m\\^2 once weekly","id":"OG001","title":"Vinorelbine"}],"paramType":"NUMBER","populationDescription":"The secondary efficacy analysis (DCR) was performed in the ITT (Intent-to-treat) analysis set.","reportingStatus":"POSTED","timeFrame":"Up to approx. 40 months (data cut-off: 06-Apr-2018) - Time from randomization until death from any cause.","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}